Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients.

T Kuusi(University of Helsinki), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), Hannele Yki‐Järvinen(University of Helsinki), M. Valle(University of Helsinki), Christian Ehnholm(University of Helsinki), Markku S. Nieminen(Cornell University), Esko A. Nikkilä(Cegep de Sept Iles)
Arteriosclerosis An Official Journal of the American Heart Association Inc
March 1, 1989
10.1161/01.atv.9.2.237
Cited by 161

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
|New England Journal of Medicine|1987|3.9k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k